ArticleEmerging infectious diseases2015
Mycobacterium abscessus Complex Infections in Humans.
Article in Emerging infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 306 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
306 citing papers in PubMed, 502 citations in OpenAlex.
- Pharmacokinetics of Omadacycline in Adults with Cystic Fibrosis.Clinical pharmacokinetics · 2024Trial
- Notes from the Field: Nontuberculous Mycobacteria Infections After Cosmetic Surgery Procedures in Mexico - United States, April-September 2025.MMWR. Morbidity and mortality weekly report · 2026Article
- Investigation of Mycobacterium abscessus Cluster in Hospital, Maryland, USA, 2024.Emerging infectious diseases · 2026Review
- The SigD regulon of Mycobacterium abscessus determines cell envelope composition and antibiotic susceptibility.PLoS genetics · 2026Article
- Genetic diversity and clinical spectrum ofIJID regions · 2026Article
- Assessing Metal Ion Assignment Accuracy in Protein Data Bank Models via Elemental Spectroscopy.Journal of chemical information and modeling · 2026Article
- Expanding the scope of Mycobacterium abscessus reference strains to improve pulmonary disease modeling.Disease models & mechanisms · 2026Article
- Utility of RGM medium for recovery ofIranian journal of microbiology · 2026Article
- Article
- Novel Hawai'i and Pacific Island circulating clusters ofApplied and environmental microbiology · 2026Article
- Article
- Injection-Site Abscess Caused by Mycobacterium abscessus Following Testosterone Injection: A Case Report.Cureus · 2026Article
- Article
- Microbiome signatures of mangroves and salt marsh halophyte rhizosphere soil sediments: a metagenomic approach.Scientific reports · 2026Article
- A Division-Associated Envelope Protein, MAB_2363, Drives Intrinsic Resistance and Virulence inMicroorganisms · 2026Article
- Peritoneal Dialysis-RelatedClinical case reports · 2026Article
- TheMicrobiology spectrum · 2026Article
- A hidden threat: a case of relapsed disseminatedJournal of bone and joint infection · 2026Article
- Successful treatment ofRespiratory medicine case reports · 2026Article
- Zebrafish larvae swim bladder serves as a model to studyMycobacteria (London, England) · 2026Article
246 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycobacterium abscessus complex comprises a group of rapidly growing, multidrug-resistant, nontuberculous mycobacteria that are responsible for a wide spectrum of skin and soft tissue diseases, central nervous system infections, bacteremia, and ocular and other infections. M. abscessus complex is differentiated into 3 subspecies: M. abscessus subsp. abscessus, M. abscessus subsp. massiliense, and M. abscessus subsp. bolletii. The 2 major subspecies, M. abscessus subsp. abscessus and M. abscessus subsp. massiliense, have different erm(41) gene patterns. This gene provides intrinsic resistance to macrolides, so the different patterns lead to different treatment outcomes. M. abscessus complex outbreaks associated with cosmetic procedures and nosocomial transmissions are not uncommon. Clarithromycin, amikacin, and cefoxitin are the current antimicrobial drugs of choice for treatment. However, new treatment regimens are urgently needed, as are rapid and inexpensive identification methods and measures to contain nosocomial transmission and outbreaks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.